UNSPSC 51182705: Metformin/pioglitazone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182705 Metformin/pioglitazone is a Commodity code, but the recent state and local opportunities posted under it show a significant mismatch: the code nominally covers specific diabetes medications, yet the indexed opportunities concern naloxone procurement and direct-to-manufacturer pharmacy initiatives unrelated to the code's drug class. State and local procurement activity under this code shows little relevant recent focus. The mismatch suggests either tagging error in the source data or that the code has fallen out of active use for traditional pharmaceutical supply contracts.

The two indexed opportunities—Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, with response due July 26, 2023) and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026, response due April 3, 2026)—do not represent procurement of metformin or pioglitazone products. Without recent solicitations actually purchasing the medications the code describes, the geographic spread and issuing-body mix cannot be characterized from this source. A business development professional pursuing state and local contracts for diabetes pharmaceuticals should verify current UNSPSC coding practices with procurement offices directly rather than rely on this code's recent activity.